NEVRO CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.32 USD | -2.58% |
|
-6.21% | -47.40% |
| 15/04 | RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating | MT |
| 11/04 | Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating | MT |
Chart calendar Nevro Corp.
710c07fa8097d79d537f112efd1b2.HPDqtDPUaPYxaNExZU9l6TuW1KkKUOE4OerWHw65MQA.Upia9VSdAr9yA6laHQ4zjmT65v1VBq1PabiTfj3qA05MuoThUZUPmn5ctg~605a8582f4c3091bb0232e38fbf50869
Upcoming events on Nevro Corp.
Past events on Nevro Corp.
| 22/02/2024 03:00 am | Q4 2023 Earnings Call |
| 22/02/2024 02:35 am | Q4 2023 Earnings Release |
| 21/01/2024 06:44 am | North American Neuromodulation Society Meeting - Leonardo Kapural, M.D. |
| 21/01/2024 | North American Neuromodulation Society Meeting - Neuromodulation and Athletics. Parallels and Lesson |
| 21/01/2024 03:45 am | North American Neuromodulation Society Meeting - Johnathan Goree, M.D. |
| 21/01/2024 03:00 am | North American Neuromodulation Society Meeting |
| 21/01/2024 01:30 am | North American Neuromodulation Society Meeting - Lunch Symposium |
| 21/01/2024 12:42 am | North American Neuromodulation Society Meeting - Dongchul Lee |
| 21/01/2024 12:10 am | North American Neuromodulation Society Meeting - David Caraway, M.D. |
| 21/01/2024 12:00 am | North American Neuromodulation Society Meeting - Scientific Advances in Neuromodulation Session |
| 11/01/2024 09:45 pm | J.P. Morgan Healthcare Conference |
| 02/11/2023 02:00 am | Q3 2023 Earnings Call |
| 02/11/2023 01:31 am | Q3 2023 Earnings Release |
| 11/09/2023 10:25 pm | Morgan Stanley Global Healthcare Conference |
| 08/09/2023 02:00 am | Wells Fargo Healthcare Conference |
| 09/08/2023 06:00 pm | Canaccord Genuity Growth Conference |
| 02/08/2023 02:00 am | Q2 2023 Earnings Call |
| 02/08/2023 01:33 am | Q2 2023 Earnings Release |
| 15/07/2023 09:30 pm | American Society of Pain & Neuroscience Conference |
| 15/07/2023 06:31 pm | American Society of Pain & Neuroscience Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 390 388 0.6% | 362 360 0.68% | 387 385 0.61% | 406 406 0.01% | 425 425 0.05% | 441 |
|
EBITDA Million USD | Released Forecast Spread | -82,0 -85,9 4.51% | -3,86 -15,3 74.82% | -17,2 -21,3 19.35% | -23,8 -21,6 -10.17% | -17,7 -24,2 26.89% | -11,7 |
|
EBIT Million USD | Released Forecast Spread | -86,7 -95,4 9.07% | -62,9 -68,9 8.73% | -111 -106 -4.91% | 6,16 8,90 -30.72% | -99,3 -105 5.25% | -89,3 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -102 -101 -1.02% | -82,2 -86,3 4.8% | -131 -117 -11.97% | 4,26 -23,0 118.55% | -97,9 -99,6 1.75% | -95,5 |
|
Net income Million USD | Released Forecast Spread | -104 -110 5.7% | -83,1 -87,4 5.01% | -131 -125 -5.35% | 3,00 -14,7 120.4% | -92,2 -101 8.95% | -96,0 |
|
EPS USD | Released Forecast Spread | -3,37 -3,58 5.97% | -2,47 -2,61 5.34% | -3,77 -3,63 -3.75% | 0,08 -0,78 110.26% | -2,56 -2,81 8.98% | -2,65 |
| Announcement Date | 25/02/20 | 24/02/21 | 23/02/22 | 16/02/23 | 21/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 103 101 2.04% | 87,8 86,2 1.92% | 104 104 -0.25% | 100 99,2 1.32% | 114 114 0.13% | 96,3 95,4 1.02% | 109 108 0.69% | 104 95,9 8.32% | 116 116 0.16% | 97,9 | 111 | 108 | 123 | 104 |
|
EBITDA Million USD | Released Forecast Spread | -7,51 -10,3 26.75% | -14,1 -19,7 28.61% | -4,49 -6,68 32.77% | -3,80 -7,74 50.99% | -1,44 1,08 -233.55% | -17,1 -20,0 14.45% | -3,13 -4,84 35.49% | -5,80 -9,23 37.24% | 8,37 1,19 605.35% | -15,6 | -2,74 | -2,62 | 9,04 | -13,1 |
|
EBIT Million USD | Released Forecast Spread | -26,2 -26,5 1.18% | -32,8 -35,5 7.82% | -23,8 -25,3 6.07% | 82,1 4,98 1547.06% | -19,4 -17,0 -13.62% | -36,3 -36,5 0.59% | -25,6 -24,8 -3.46% | -25,6 -28,1 8.98% | -11,8 -18,2 35.15% | -36,1 | -22,2 | -21,6 | -10,4 | -31,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -30,2 -27,9 -8.16% | -34,1 -37,9 9.82% | -24,7 -27,3 9.2% | 82,0 16,3 403% | -18,8 -17,9 -5.14% | -34,7 -37,0 6.31% | -24,2 -23,9 -1.39% | -23,3 -28,7 18.78% | -15,6 -17,4 10.56% | -38,4 | -23,9 | -23,1 | -12,5 | -33,5 |
|
Net income Million USD | Released Forecast Spread | -30,1 -29,8 -1.17% | -34,3 -38,8 11.55% | -25,0 -28,0 10.7% | 81,5 7,33 1011.34% | -19,2 -18,1 -6.04% | -35,0 -37,2 5.76% | -24,7 -24,5 -1.01% | -23,5 -27,8 15.45% | -8,98 -17,6 49.05% | -38,8 | -24,3 | -23,3 | -11,8 | -33,7 |
|
EPS USD | Released Forecast Spread | -0,86 -0,86 -0.33% | -0,98 -1,10 10.96% | -0,71 -0,80 11.58% | 2,22 -0,10 2391.49% | -0,54 -0,49 -10.58% | -0,98 -1,04 5.69% | -0,69 -0,69 0.15% | -0,65 -0,77 15.49% | -0,25 -0,49 48.96% | -1,05 | -0,66 | -0,62 | -0,33 | -0,81 |
| Announcement Date | 23/02/22 | 04/05/22 | 03/08/22 | 02/11/22 | 16/02/23 | 26/04/23 | 01/08/23 | 01/11/23 | 21/02/24 | - | - | - | - | - |
More events
Past sector events for Nevro Corp.
| 27/04/2024 | BLUE SAIL MEDICAL CO.,LTD.: Q1 2024 Earnings Release |
| 27/04/2024 | BLUE SAIL MEDICAL CO.,LTD.: Q4 2023 Earnings Release |
| 26/04/2024 03:30 pm | AVANTOR, INC.: Q1 2024 Earnings Release |
| 26/04/2024 | MOTIC (XIAMEN) ELECTRIC GROUP CO.,LTD: Q1 2024 Earnings Release |
| 26/04/2024 | MICRO-TECH (NANJING) CO.,LTD: Q1 2024 Earnings Release |
| 26/04/2024 | SINOCARE INC.: Q4 2023 Earnings Release |
| 26/04/2024 | JAFRON BIOMEDICAL CO.,LTD.: Q1 2024 Earnings Release |
| 26/04/2024 | MICRO-TECH (NANJING) CO.,LTD: Q4 2023 Earnings Release |
| 26/04/2024 | JAFRON BIOMEDICAL CO.,LTD.: Q4 2023 Earnings Release |
| 26/04/2024 | SINOCARE INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- NVRO Stock
- Calendar Nevro Corp.
